Holen Sie sich die Stockscreener-App
38.48
4.88%
1.79
Schlusskurs vom Vortag:
$36.69
Offen:
$37.3
24-Stunden-Volumen:
1.40M
Relative Volume:
2.67
Marktkapitalisierung:
$1.16B
Einnahmen:
$1.37B
Nettoeinkommen (Verlust:
$54.85M
KGV:
21.70
EPS:
1.7729
Netto-Cashflow:
$123.71M
1W Leistung:
+13.75%
1M Leistung:
+6.01%
6M Leistung:
-10.32%
1J Leistung:
-28.17%
1-Tages-Spanne:
$36.41
$38.83
1-Wochen-Bereich:
$32.64
$38.83
52-Wochen-Spanne:
$31.44
$56.63
Conmed Corp Stock (CNMD) Company Profile
Firmenname
Conmed Corp
Sektor
Branche
Telefon
727-214-2974
Adresse
11311 CONCEPT BOULEVARD, LARGO, NY
Compare CNMD vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNMD
Conmed Corp
|
38.48 | 1.16B | 1.37B | 54.85M | 123.71M | 1.7729 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Conmed Corp Stock (CNMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-06-12 | Herabstufung | Needham | Buy → Hold |
| 2025-04-28 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-01 | Bestätigt | Needham | Buy |
| 2023-05-22 | Eingeleitet | CL King | Buy |
| 2023-03-27 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-03-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2021-10-06 | Hochstufung | Needham | Hold → Buy |
| 2021-07-15 | Eingeleitet | UBS | Buy |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2019-11-26 | Herabstufung | Needham | Buy → Hold |
| 2019-11-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-10-31 | Bestätigt | Needham | Buy |
| 2019-10-04 | Bestätigt | Needham | Buy |
| 2019-08-22 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-04-18 | Eingeleitet | Stifel | Buy |
| 2019-04-16 | Bestätigt | Needham | Buy |
| 2019-01-23 | Bestätigt | Needham | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Equal Weight |
| 2018-08-07 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-04-26 | Bestätigt | Needham | Buy |
| 2018-02-01 | Bestätigt | Needham | Buy |
| 2017-07-27 | Bestätigt | Needham | Buy |
| 2017-04-27 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2017-04-27 | Bestätigt | Needham | Buy |
| 2016-11-18 | Bestätigt | Needham | Buy |
| 2016-07-28 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2016-04-28 | Bestätigt | Needham | Buy |
| 2015-10-22 | Bestätigt | Northland Capital | Market Perform |
Alle ansehen
Conmed Corp Aktie (CNMD) Neueste Nachrichten
A Look at Conmed Corp (CNMD) After 4.9% Gain -- GF Value $74.38 vs Price $38.48 - GuruFocus
Conmed shares jump on potential sale report - Investing.com
Conmed shares jump on potential sale report By Investing.com - Investing.com UK
CONMED (NYSE:CNMD) Upgrade Puts Recovery In Focus - Kalkine Media
CONMED (NYSE:CNMD) Upgraded at BMO Capital Markets - MarketBeat
CONMED (NYSE:CNMD) Stock Price Up 11.6%Still a Buy? - MarketBeat
CNMD stock holds steady as focus shifts to the business - Ad-hoc-news.de
CONMED (CNMD) Stock Fair Value Moves Lower As Analysts Turn More Cautious - Yahoo Finance
CONMED stock centers on its medical device platform - Ad-hoc-news.de
CONMED (NYSE:CNMD) Sparks Value Debate After Slide - Kalkine Media
CONMED Corporation (CNMD) Rallies 3.27% as Support Holds FirmPairs Trade - dars.gov.et
Form 4 CONMED Corporation For: 2 July By Investing.com - Investing.com Canada
Director at CONMED (CNMD) receives grant of 5,603 restricted stock units - Stock Titan
Director Jeffrey Mirviss granted 5,603 RSUs at CONMED (NYSE: CNMD) - Stock Titan
New CONMED (CNMD) director Jeffrey Mirviss reports no common stock holdings - Stock Titan
New CONMED (CNMD) director Celine Christine Martin reports no common stock holdings - Stock Titan
CONMED schedules Q2 results call for July 29 after market close - Stock Titan
Why CONMED (CNMD) Shares Are Falling Today - Yahoo! Finance Canada
BofA downgrades Conmed stock rating on growth concerns - Investing.com
Here's why you should retain CONMED stock in your portfolio now - MSN
CNMD Forecast — Price Target — Prediction for 2027 - TradingView
Conmed Corp (CNMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CNMD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Will CONMED’s New CFO Shift CNMD’s Financial Playbook Or Deepen Its Existing Strategy? - Yahoo Finance
CONMED Corp. Stock Plummets to New 52-Week Low of $31.86 - MarketsMojo
CONMED Corp. Stock Hits Day Low of $31.86 Amid Price Pressure - MarketsMojo
Conmed Corp (CNMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CONMED Appoints John E. Gallagher as New Chief Financial Officer, Effective July 2026 - Minichart
Conmed Corp (CNMD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Conmed Corp (CNMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Conmed Corp (CNMD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Conmed Corp (CNMD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Conmed Corp (CNMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Conmed Corp (CNMD) Institutional Confidence - TradingKey
Conmed Corp (CNMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Conmed names John Gallagher as CFO effective July 15 - Investing.com
CONMED names John E. Gallagher as EVP & CFO, Patrick Beyer steps down as interim PFO - TradingView
CONMED (NYSE: CNMD) hires John Gallagher as CFO with equity-heavy pay - Stock Titan
Conmed names John Gallagher as CFO effective July 15 By Investing.com - Investing.com UK
CONMED picks John Gallagher as CFO in July leadership change - Stock Titan
Conmed Corporation stock hits 52-week low at 32.1 USD - Investing.com
Discipline and Rules-Based Execution in CNMD Response - Stock Traders Daily
CONMED Corp stock (US2074101013): Medtech mid-cap in focus after latest earnings and guidance update - AD HOC NEWS
CONMED Corp stock (US2074101013): medtech growth story after latest earnings update - Ad-hoc-news.de
CONMED to Repurchase $645.2 Million of 2027 Convertible Notes for $637.2 Million Cash - TradingView
CONMED (CNMD) to buy back $645.2M of 2.25% convertible notes due 2027 - Stock Titan
Director at CONMED (NYSE: CNMD) exercises 668 RSUs and receives 5,772-unit equity award - Stock Titan
CONMED (NYSE: CNMD) director gets 5,772 RSUs, converts 668 units - Stock Titan
Director at CONMED (NYSE: CNMD) receives 5,772 RSUs under 2025 incentive plan - Stock Titan
CONMED (NYSE: CNMD) director awarded 5,772 RSUs and exercises 668 into shares - Stock Titan
Director Mark Kaye receives 5,772 RSUs at CONMED (NYSE: CNMD) - Stock Titan
Finanzdaten der Conmed Corp-Aktie (CNMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):